Use of guideline-recommended therapies for heart failure in the medicare population

Clinical Cardiology

Volumn 33, Issue 7, 2010, Pages 400-405

  DiMartino, Lisa D ^a   Shea, Alisa M ^a   Hernandez, Adrian F ^a,b   Curtis, Lesley H ^a,b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CARDIOVASCULAR AGENT;

AGED; ARTICLE; DRUG USE; FEMALE; HEALTH INSURANCE; HEART FAILURE; HUMAN; MALE; PRACTICE GUIDELINE; PRESCRIPTION; SELF REPORT; CLINICAL PRACTICE; DRUG UTILIZATION; HEALTH CARE SURVEY; MEDICARE; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UNITED STATES;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR AGENTS; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HEART FAILURE; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; LOGISTIC MODELS; MALE; MEDICARE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 77954975051     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20760     Document Type: Article

References (29)

1. Curtis LH, Whellan DJ, Hammill BG, et al. Incidence and prevalence of heart failure in elderly persons, 1994-2003. Arch Intern Med. 2008;168:418-424.
2. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee [published correction appears in Circulation. 2009;119:e182]. Circulation. 2009;119:480-486.
3. Curtis LH, Greiner MA, Hammill BG, et al. Early and long-term outcomes of heart failure in elderly persons, 2001-2005. Arch Intern Med. 2008;168:2481-2488.
4. Setoguchi S, Levin R, Winkelmayer WC. Long-term trends of angiotensin-converting enzyme inhibitor and angiotensin-receptor blocker use after heart failure hospitalization in community-dwelling seniors. Int J Cardiol. 2008;125:172-177. (Pubitemid 351400230)
5. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112:e154-e235.
6. Hernandez AF, Hammill BG, O'Connor CM, et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) registry. J Am Coll Cardiol. 2009;53:184-192.
7. Butler J, Arbogast PG, Daugherty J, et al. Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge. J Am Coll Cardiol. 2004;43: 2036-2043. (Pubitemid 38686798)
8. Masoudi FA, Rathore SS, Wang Y, et al. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation. 2004;110:724-731. (Pubitemid 39056273)
9. Berger AK, Duval S, Manske C, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease. Am Heart J. 2007;153:1064-1073. (Pubitemid 46823967)
10. Jencks SF, Cuerdon T, Burwen DR, et al. Quality of medical care delivered to Medicare beneficiaries: a profile at state and national levels. JAMA. 2000;284:1670-1676.
11. Masoudi FA, Baillie CA, Wang Y, et al. The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998-2001. Arch Intern Med. 2005;165: 2069-2076.
12. Adler GS. A profile of the Medicare Current Beneficiary Survey. Health Care Financ Rev. 1994;15:153-163.
13. Kamal-Bahl S, Stuart BC, Beers MH. National trends in and predictors of propoxyphene use in community-dwelling older adults. Am J Geriatr Pharmacother. 2005;3:186-195. (Pubitemid 41644457)
14. Moxey ED, O'Connor JP, Novielli KD, et al. Prescription drug use in the elderly: a descriptive analysis. Health Care Financ Rev. 2003;24:127-141. (Pubitemid 37255110)
15. Arday SL, Arday DR, Monroe S, et al. HCFA's racial and ethnic data: current accuracy and recent improvements. Health Care Financ Rev. 2000;21:107-116.
16. Fonarow GC, Abraham WT, Albert NM, et al. Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Arch Intern Med. 2007;167: 1493-1502.
17. Jackson JE, Doescher MP, Saver BG, et al. Prescription drug coverage, health, and medication acquisition among seniors with one or more chronic conditions. Med Care. 2004; 42:1056-1065.
18. Tjia J, Briesacher BA. Prescription drug benefits and use of guideline recommended medications by elderly Medicare beneficiaries with diabetes mellitus. J Am Geriatr Soc. 2008; 56: 1879-1886.
19. Steinman MA, Sands LP, Covinsky KE. Self-restriction of medications due to cost in seniors without prescription coverage. J Gen Intern Med. 2001;16:793-799.
20. The Henry J. Kaiser Family Foundation. Medicare: A Primer, 2009. http://www.kff.org/medicare/7615.cfm. Accessed October 28, 2009.
21. Hudson N. Changes in drug utilization for seniors without prior prescription drug insurance. Find Brief. 2009;12:1-3.
22. Kramer JM, Chen AY, Hammill BG, et al. Time trends and factors associated with outpatient beta-blocker use in patients with heart failure or left ventricular dysfunction. Circulation. 2004;104:e231-e184.
23. Kramer JM, Curtis LH, Dupree CS, et al. Comparative effectiveness of beta-blockers in elderly patients with heart failure. Arch Intern Med. 2008;168:2422-2428.
24. Elam L. Dual Eligibles. The Henry J. Kaiser Family Foundation. http://www.kaiseredu.org/tutorials/Duals/Duals.html. Published 2006. Accessed September 10, 2009.
25. Setoguchi S, Glynn RJ, Avorn J, et al. Ten-year trends of cardiovascular drug use after myocardial infarction among community-dwelling persons > or = 65 years of age. Am J Cardiol. 2007;100: 1061-1067.
26. McMurray J, Cohen-Solal A, Dietz R, et al. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. Eur J Heart Fail. 2005;7:710-721.
27. Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113:203-212.
28. Federman AD, Adams AS, Ross-Degnan D, et al. Supplemental insurance and use of effective cardiovascular drugs among elderly Medicare beneficiaries with coronary heart disease. JAMA. 2001;286:1732-1739. (Pubitemid 33010259)
29. Choudhry NK, Setoguchi S, Levin R, et al. Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients. Pharmacoepidemiol Drug Saf. 2008;17: 1189-1196.